Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/85922
Title: Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye
Authors: Fan, Yanliang
Zheng, Xiaofeng
Berggren, Per-Olof
Loo, Joachim Say Chye
Yusuf Ali
Keywords: DRNTU::Science::Medicine
Allotransplantation
Drug Delivery
Issue Date: 2019
Source: Fan, Y., Zheng, X., Yusuf Ali, Berggren, P.-O., & Loo, J. S. C. (2019). Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye. Scientific Reports, 9, 3918-. doi:10.1038/s41598-019-40404-0
Series/Report no.: Scientific Reports
Abstract: The anterior chamber of the eye (ACE) has emerged as a promising clinical islet transplantation site because of its multiple advantages over the conventional intra-hepatic portal site. This includes reduced surgical invasiveness and increased islet graft survival rate. It also allows for enhanced accessibility and monitoring of the islets. Although the ACE is initially an immuno-privileged site, this privilege is disrupted once the islet grafts are re-vascularized. Given that the ACE is a confined space, achieving graft immune tolerance through local immunosuppressive drug delivery is therefore feasible. Here, we show that islet rejection in the ACE of mice can be significantly suppressed through local delivery of rapamycin by carefully designed sustained-release microparticles. In this 30-day study, allogeneic islet grafts with blank microparticles were completely rejected 18 days post-transplantation into mice. Importantly, allogeneic islet grafts co-injected with rapamycin releasing microparticles into a different eye of the same recipient were preserved much longer, with some grafts surviving for more than 30 days. Hence, islet allograft survival was enhanced by a localized and prolonged delivery of an immunosuppressive drug. We envisage that this procedure will relieve diabetic transplant recipients from harsh systemic immune suppression, while achieving improved glycemic control and reduced insulin dependence.
URI: https://hdl.handle.net/10356/85922
http://hdl.handle.net/10220/48270
DOI: 10.1038/s41598-019-40404-0
Rights: © 2019 The Author(s) (Nature Publishing Group). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:MSE Journal Articles

SCOPUSTM   
Citations

2
checked on Jun 18, 2020

WEB OF SCIENCETM
Citations 20

3
checked on Oct 22, 2020

Page view(s) 20

66
checked on Oct 21, 2020

Download(s) 20

18
checked on Oct 21, 2020

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.